Telavancin - Cumberland Pharmaceuticals
Alternative Names: Arbelic; TD-6424; Telavancin hydrochloride; VibativLatest Information Update: 21 Mar 2024
At a glance
- Originator Theravance; Theravance Biopharma
- Developer Clinigen; Cumberland Pharmaceuticals; Innoviva; MEGAPharma; PENDOPHARM; SciClone Pharmaceuticals; Theravance Biopharma; University of Illinois at Chicago
- Class Aminoglycosides; Anti-infectives; Antibacterials; Glycopeptides; Lipopeptides; Peptide antibiotics
- Mechanism of Action Cell membrane permeability enhancers; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Skin and soft tissue infections
Highest Development Phases
- Marketed Bacteraemia; Nosocomial pneumonia; Skin and soft tissue infections; Ventilator associated pneumonia
- Preregistration Bacterial infections
- Phase III Osteomyelitis
- No development reported Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 31 Dec 2023 Cumberland Pharmaceuticals has patent protection in USA related to telavancin composition of matter and methods before December 2023
- 10 Oct 2023 Clinical trials in Bacterial infections (In children) in USA (IV), prior to October 2023
- 10 Oct 2023 PK and adverse events data from a clinical trial in Bacterial infections released by Cumberland Pharmaceuticals